SCHEMBL935514

SCHEMBL935514

CSCC[C@H](NC(=O)[C@@H](N)CCC(N)=O)C(=O)O

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
FNTA P49354 8/20 0.51
FNTB P49356 8/20 0.51
PGGT1B P53609 6/20 0.51
DPP4 P27487 1/20 0.50
DPP8 Q6V1X1 1/20 0.50
DPP9 Q86TI2 1/20 0.50
ALOX15 P16050 1/20 0.47
BLM P54132 1/20 0.47
PMP22 Q01453 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5970446 1.00 LMNA (0.51) LMNAFNTAFNTBPGGT1BDPP4
SCHEMBL29592643 0.96 FNTA (0.48) LMNAFNTAFNTBPGGT1BDPP4
SCHEMBL30591103 0.96 FNTA (0.48) LMNAFNTAFNTBPGGT1BDPP4
SCHEMBL5970877 0.94 FNTA (0.48) LMNAFNTAFNTBPGGT1BDPP4
SCHEMBL2492672 0.94 FNTA (0.48) LMNAFNTAFNTBPGGT1BDPP4
SCHEMBL29376888 0.93 FNTA (0.46) LMNAFNTAFNTBPGGT1BDPP4
SCHEMBL31432555 0.92 FNTA (0.46) LMNAFNTAFNTBPGGT1BDPP4
SCHEMBL31157674 0.92 FNTA (0.46) LMNAFNTAFNTBPGGT1BDPP4
SCHEMBL30173887 0.92 FNTA (0.46) LMNAFNTAFNTBPGGT1BDPP4
SCHEMBL8749214 0.92 FNTA (0.46) LMNAFNTAFNTBPGGT1BDPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117618299-A Pleurotus rhodochrous mycelium metabolite, preparation method and application thereof 福建百想生物科技有限公司 2024-03-01 CN claimed
CN-116813690-A Selective sulfonation of benzodiazepine derivatives 伊缪诺金公司 2023-09-29 CN claimed
CN-106455664-A Composition with high content of cyclic dipeptide 三得利控股株式会社 2017-02-22 CN claimed
CN-106456633-A Sugar metabolism improving agent 三得利控股株式会社 2017-02-22 CN claimed
EP-3129909-A1 SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT Metabolon, Inc. (US) 2017-02-15 EP claimed
WO-2016124574-A1 DIAGNOSTIC TOOLS FOR ALZHEIMER'S DISEASE PHARNEXT (FR) 2016-08-11 WO claimed
WO-2015157407-A1 SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT METABOLON, INC. (US) 2015-10-15 WO claimed
EP-2454950-B1 ONION EXTRACT, AND PROCESS FOR PRODUCTION THEREOF TAKASAGO PERFUMERY CO LTD (JP) 2014-09-03 EP claimed
EP-2454950-A1 ONION EXTRACT, AND PROCESS FOR PRODUCTION THEREOF Takasago International Corporation (JP) 2012-05-23 EP claimed
US-20120114827-A1 ONION EXTRACT, AND PROCESS FOR PRODUCTION THEREOF TAKASAGO INTERNATIONAL CORPORATION (JP) 2012-05-10 US claimed
US-20260117315-A1 KEY PREDOMINANT SPECIES OF GUT BACTERIA COLONIZING FARM-EXPOSED INFANTS WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2026-04-30 US disclosed
US-20250099623-A1 COMPOSITIONS AND METHODS FOR ENHANCING INTRA-MITOCHONDRIAL PROTEIN TRANSLATION AND OXIDATIVE PHOSPHORYLATION THE BROAD INSTITUTE, INC. (US) 2025-03-27 US disclosed
US-12259397-B2 Biomarkers related to organ function University of Pittsburgh—of the Commonwealth System of Higher Education (US) 2025-03-25 US disclosed
US-20250074942-A1 COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E CALICO LIFE SCIENCES LLC (US) 2025-03-06 US disclosed
CN-118581067-A Method for selecting high M6P recombinant proteins 阿米库斯治疗学公司 2024-09-03 CN disclosed
US-20070292916-A1 MUTANT PROTEIN HAVING THE PEPTIDE-SYNTHESIZING ACTIVITY AJINOMOTO CO., INC. (JP) 2007-12-20 US disclosed
EP-1829968-A1 MUTANT PROTEIN HAVING PEPTIDE-PRODUCTION ACTIVITY Ajinomoto Co., Inc. (JP) 2007-09-05 EP disclosed
US-20070190602-A1 Mutant protein having the peptide-synthesizing activity AJINOMOTO CO., INC (JP) 2007-08-16 US disclosed
US-20060217321-A1 Compositions to improve tic disorders TAIYOKAGAKU CO., LTD. (JP) 2006-09-28 US disclosed
US-20060188976-A1 Mutant protein having the peptide-synthesizing activity AJINOMOTO CO. INC (JP) 2006-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260117315-A1 KEY PREDOMINANT SPECIES OF GUT BACTERIA COLONIZING FARM-EXPOSED INFANTS FABP2, IL5, FZD7 LMNA 1537/4885FNTA 2666/4885FNTB 1120/4885
US-20250074942-A1 COMPOSITIONS AND METHODS FOR COVALENT PEPTIDE-BASED MODULATORS OF HLA-E MICA, CD74, HLA-DRB1 LMNA 3512/4885FNTA 3629/4885FNTB 2486/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.